Home » Stocks » Smith & Nephew

Smith & Nephew PLC (SNN)

Stock Price: $41.07 USD -0.92 (-2.19%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 17.95B
Revenue (ttm) 4.69B
Net Income (ttm) 600.00M
Shares Out 437.80M
EPS (ttm) 0.89
PE Ratio 46.15
Forward PE 30.49
Dividend $0.75
Dividend Yield 1.83%

Stock Quote

Trading Day Aug 14, 2020
Last Price $41.07
Previous Close $41.99
Change ($) -0.92
Change (%) -2.19%
Day's Open 41.41
Day's Range 40.94 - 41.47
Day's Volume 167,640
52-Week Range 26.07 - 52.26

More Stats

Market Cap 17.95B
Enterprise Value 19.72B
Earnings Date (est) n/a
Ex-Dividend Date Apr 2, 2020
Shares Outstanding 437.80M
Float 433.03M
EPS (basic) 1.372
EPS (diluted) 0.89
FCF / Share 2.17
Dividend $0.75
Dividend Yield 1.83%
Earnings Yield 2.17%
FCF Yield 5.36%
Payout Ratio n/a
Shares Short 636,206
Short Ratio 1.32
Short % of Float n/a
Beta 0.24
PE Ratio 46.15
Forward PE 30.49
P/FCF Ratio 18.66
PS Ratio 3.83
PB Ratio 3.72
Revenue 4.69B
Operating Income 815.00M
Net Income 600.00M
Free Cash Flow 962.00M
Net Cash -1.77B
Net Cash / Share -4.05
Gross Margin 81.21%
Operating Margin 17.38%
Profit Margin 11.70%
FCF Margin 20.52%
ROA 3.59%
ROE 7.89%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 7
Overweight 0
Hold 3
Underweight 0
Sell 2

Analyst Consensus: Overweight

Price Target

(14.73% upside)
Current: $41.07
Target: 47.12
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth4.77%2.92%2.06%0.76%0.37%6.11%5.17%-3.11%7.77%-
Gross Profit3,8003,6063,5173,3973,4913,4553,2513,0673,1302,931
Operating Income815863934801628749810846862920
Net Income600663767784410501556721575615
Shares Outstanding888891904915951918964951951951
Earnings Per Share1.371.511.751.760.911.111.231.601.281.38
EPS Growth-9.64%-13.68%-0.11%92.54%-18.13%-9.28%-23.25%24.61%-7.23%-
Dividend Per Share0.730.720.610.630.601.051.301.020.790.72
Dividend Growth0.55%19.47%-3.19%4.68%-43.05%-19.23%27.45%29.11%9.72%-
Operating Cash Flow1,3701,1081,2731,0351,2039611,1381,1841,1351,111
Capital Expenditures-408-347-376-392-358-355-340-265-321-307
Free Cash Flow962761897643845606798919814804
Cash & Equivalents27736516910012093.00137178184207
Total Debt2,0471,4651,4501,6501,4801,705391468322699
Net Cash / Debt-1,770-1,100-1,281-1,550-1,360-1,612-254-290-138-492
Book Value5,1414,8744,6443,9583,9664,0404,0473,8843,1872,773
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Smith & Nephew PLC
Country United Kingdom
Employees 17,500
CEO Roland D. Diggelmann

Stock Information

Ticker Symbol SNN
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Devices
Unique Identifier NYSE: SNN
IPO Date November 16, 1999


Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.